Toshihiro Tanaka, Weici Zhang, Ying Sun, Zongwen Shuai, Asiya Seema Chida, Thomas P. Kenny, Guo‐Xiang Yang, Ignacio Sanz, Aftab Ansari, Christopher L. Bowlus, Gregory C. Ippolito, Ross L. Coppel, Kazuichi Okazaki, Xiao‐Song He, Patrick S.C. Leung, M. Eric Gershwin – 3 May 2017 – A major problem in autoimmunity has been identification of the earliest events that lead to breach of tolerance.

Steven P. O'Hara, Nicholas F. La Russo – 2 May 2017

Wei Li, Tohti Amet, Yanyan Xing, Dennis Yang, Suthat Liangpunsakul, Puneet Puri, Patrick S. Kamath, Arun J. Sanyal, Vijay H. Shah, Barry P. Katz, Svetlana Radaeva, David W. Crabb, Naga Chalasani, Qigui Yu – 2 May 2017 – Alcoholic hepatitis (AH) develops in only a small proportion of heavy drinkers. To better understand the mechanisms underlying this disparity, we conducted a study to define the relationship between AH development and dysregulated immune responses that might be ameliorated by alcohol abstinence.

Alexandre Louvet, Julien Labreuche, Florent Artru, Alexis Bouthors, Benjamin Rolland, Pierre Saffers, Julien Lollivier, Elise Lemaître, Sébastien Dharancy, Guillaume Lassailly, Valérie Canva‐Delcambre, Alain Duhamel, Philippe Mathurin – 29 April 2017 – Understanding the mechanisms of outcome according to the time frame can help optimize the therapeutic development in severe alcoholic hepatitis.

Alexandre Louvet, Julien Labreuche, Florent Artru, Alexis Bouthors, Benjamin Rolland, Pierre Saffers, Julien Lollivier, Elise Lemaître, Sébastien Dharancy, Guillaume Lassailly, Valérie Canva‐Delcambre, Alain Duhamel, Philippe Mathurin – 29 April 2017 – Understanding the mechanisms of outcome according to the time frame can help optimize the therapeutic development in severe alcoholic hepatitis.

28 April 2017

28 April 2017

Thoetchai (Bee) Peeraphatdit, Patrick S. Kamath, Vijay H. Shah – 27 April 2017

Ahmed Diab, Adrien Foca, Floriane Fusil, Thomas Lahlali, Pascal Jalaguier, Fouzia Amirache, Lia N'Guyen, Nathalie Isorce, François‐Loïc Cosset, Fabien Zoulim, Ourania Andrisani, David Durantel – 26 April 2017 – Chronic hepatitis B virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC) and current treatments for chronic hepatitis B and HCC are suboptimal. Herein, we identified cellular serine/threonine Polo‐like‐kinase 1 (PLK1) as a positive effector of HBV replication.

Ahmed Diab, Adrien Foca, Floriane Fusil, Thomas Lahlali, Pascal Jalaguier, Fouzia Amirache, Lia N'Guyen, Nathalie Isorce, François‐Loïc Cosset, Fabien Zoulim, Ourania Andrisani, David Durantel – 26 April 2017 – Chronic hepatitis B virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC) and current treatments for chronic hepatitis B and HCC are suboptimal. Herein, we identified cellular serine/threonine Polo‐like‐kinase 1 (PLK1) as a positive effector of HBV replication.